Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma

Moving to a World Beyond “p 

(2019) Ronald L. Wasserstein et al.   AMERICAN STATISTICIAN

Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma

(2018) Vincenzo Mazzaferro et al.   GASTROENTEROLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study

(2017) P. Broadhurst et al.   JOURNAL OF HEPATOLOGY

Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

(2017) Jordi Bruix et al.   JOURNAL OF HEPATOLOGY

Per-Protocol Analyses of Pragmatic Trials

(2017) Miguel A. Hernán et al.   NEW ENGLAND JOURNAL OF MEDICINE